Hematolojik Malignite Hastaları, COVID-19 ve Favipiravir

Kaynakça (5)

1. Civriz Bozdağ S, Cengiz Seval G, Yönal Hindilerden İ, Hindilerden F, Andıç N, Baydar M, Aydın Kaynar L, Koçak Toprak S, Göksoy HS, Balık Aydın B, Demirci U, Can F, Özkocaman V, Gündüz E, Güven ZT, Özkurt ZN, Demircioğlu S, Beksaç M, İnce İ, Yılmaz U, Eroğlu Küçükdiler H, Abishov E, Yavuz B, Ataş Ü, Mutlu YG, Baş V, Özkalemkaş F, Üsküdar Teke H, Gürsoy V, Çelik S, Çiftçiler R, Yağcı M, Topçuoğlu P, Çeneli Ö, Abbasov H, Selim C, Ar MC, Yücel OK, Sadri S, Albayrak C, Demir AM, Güler N, Keklik M, Terzi H, Doğan A, Yegin ZA, Kurt Yüksel M, Sadri S, Yavaşoğlu İ, Beköz HS, Aksu T, Maral S, Erol V, Kaynar L, İlhan O, Bolaman AZ, Sevindik ÖG, Akyay A, Özcan M, Gürman G, Ünal Ş, Yavuz Y, Diz Küçükkaya R, Özsan GH. Clinical characteristics and outcomes of COVID-19 in Turkish hematological malignancy patients. Turk J Hematol 2021. doi: 10.4274/tjh.galenos.2021.2021.0287. Epub ahead of print. PMID: 34521187
2. Çınarka H, Günlüoğlu G, Çörtük M, Yurt S, Kıyık M, Koşar F, Tanrıverdi E, Arslan MA, Baydili KN, Koç AS, Altın S, Çetinkaya E. The comparison of favipiravir and lopinavir/ritonavir combination in COVID-19 treatment. Turk J Med Sci 2021;51:1624-1630
3. Murohashi K, Hagiwara E, Kitayama T, Yamaya T, Higa K, Sato Y, Otoshi R, Shintani R, Okabayashi H, Ikeda S, Niwa T, Nakazawa A, Oda T, Okuda R, Sekine A, Kitamura H, Baba T, Komatsu S, Iwasawa T, Kaneko T, Ogura T. Outcome of early-stage combination treatment with favipiravir and methylprednisolone for severe COVID-19 pneumonia: a report of 11 cases. Respir Investig 2020;58:430-434
4. Fujii S, Ibe Y, Ishigo T, Inamura H, Kunimoto Y, Fujiya Y, Kuronuma K, Nakata H, Fukudo M, Takahashi S. Early favipiravir treatment was associated with early defervescence in non-severe COVID-19 patients. J Infect Chemother 2021;27:1051-1057
5. Doi Y, Hibino M, Hase R, Yamamoto M, Kasamatsu Y, Hirose M, Mutoh Y, Homma Y, Terada M, Ogawa T, Kashizaki F, Yokoyama T, Koba H, Kasahara H, Yokota K, Kato H, Yoshida J, Kita T, Kato Y, Kamio T, Kodama N, Uchida Y, Ikeda N, Shinoda M, Nakagawa A, Nakatsumi H, Horiguchi T, Iwata M, Matsuyama A, Banno S, Koseki T, Teramachi M, Miyata M, Tajima S, Maeki T, Nakayama E, Taniguchi S, Lim CK, Saijo M, Imai T, Yoshida H, Kabata D, Shintani A, Yuzawa Y, Kondo M. A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19. Antimicrob Agents Chemother 2020;64:e01897-20.